Beta-blockers in cirrhosis: Evidence-based indications and limitations

Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in the setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in preventing initial variceal bleeding and subsequent rebleeding. Recent evidence indicates that NSBBs could prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Susana G., Mendoza, Yuly P., Bosch, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005550/
https://www.ncbi.nlm.nih.gov/pubmed/32039404
http://dx.doi.org/10.1016/j.jhepr.2019.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005550/
https://www.ncbi.nlm.nih.gov/pubmed/32039404
http://dx.doi.org/10.1016/j.jhepr.2019.12.001

Ejemplares similares